MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · IEX Real-Time Price · USD
-0.68 (-2.44%)
At close: May 31, 2023, 4:00 PM
-0.14 (-0.51%)
After-hours: May 31, 2023, 7:39 PM EDT

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.

The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics
MoonLake Immunotherapeutics logo
Country Switzerland
Founded 2021
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Dr. Jorge Santos da Silva

Contact Details

Dorfstrasse 29
Zug, V8 6300
Phone 41 41 510 8022

Stock Details

Ticker Symbol MLTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821586
CUSIP Number 61559X104
SIC Code 2834

Key Executives

Name Position
Dr. Jorge Santos da Silva Co-Founder, Chief Executive Officer and Director
Dr. Kristian Reich Co-Founder and Chief Scientific Officer
Matthias Bodenstedt Chief Financial Officer
Oliver Daltrop Chief Technical Officer
Nuala Brennan Chief Clinical Development Officer

Latest SEC Filings

Date Type Title
May 19, 2023 8-K Current Report
May 11, 2023 424B5 Filing
May 11, 2023 10-Q Quarterly Report
May 9, 2023 EFFECT Notice of Effectiveness
May 4, 2023 EFFECT Notice of Effectiveness
May 1, 2023 S-3 Registration statement under Securities Act of 1933
May 1, 2023 POS AM Post-Effective amendments for registration statement
Apr 26, 2023 ARS Filing
Apr 26, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2023 DEF 14A Other definitive proxy statements